Nevro (NVRO) Set to Announce Earnings on Tuesday

Nevro (NYSE:NVRO) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 6th. Analysts expect Nevro to post earnings of ($0.63) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Nevro (NYSE:NVRO) last announced its earnings results on Tuesday, May 7th. The medical equipment provider reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.32. Nevro had a negative return on equity of 27.48% and a negative net margin of 19.17%. The firm had revenue of $101.90 million during the quarter, compared to analyst estimates of $97.90 million. During the same period last year, the firm posted ($0.98) EPS. The business’s revenue was up 5.8% compared to the same quarter last year. On average, analysts expect Nevro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nevro Trading Down 1.4 %

Shares of NVRO opened at $9.05 on Monday. The business has a 50-day moving average of $9.07 and a 200 day moving average of $12.29. Nevro has a fifty-two week low of $7.46 and a fifty-two week high of $22.64. The firm has a market cap of $332.41 million, a P/E ratio of -3.95 and a beta of 0.91. The company has a debt-to-equity ratio of 0.77, a quick ratio of 5.57 and a current ratio of 7.38.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Truist Financial decreased their price objective on Nevro from $11.00 to $10.00 and set a “hold” rating for the company in a report on Tuesday, July 16th. Morgan Stanley cut their target price on Nevro from $14.00 to $9.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Piper Sandler cut their target price on Nevro from $15.00 to $12.00 and set an “underweight” rating for the company in a research note on Wednesday, May 8th. Wells Fargo & Company cut their target price on Nevro from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 8th. Finally, Mizuho dropped their target price on Nevro from $20.00 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, April 11th. Two research analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the stock. Based on data from MarketBeat.com, Nevro has an average rating of “Hold” and an average price target of $14.11.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.